Camptothecin - Cerulean Pharma

Drug Profile

Camptothecin - Cerulean Pharma

Alternative Names: CRLX 101; Cyclosert™-enhanced camptothecin; IT-101

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator Insert Therapeutics
  • Developer AstraZeneca; Beth Israel Deaconess Medical Center; Brigham and Womens Hospital; Cerulean Pharma; Dana-Farber Cancer Institute; Massachusetts General Hospital; National Cancer Institute (USA); University of North Carolina
  • Class Antineoplastics; Camptothecins; Drug conjugates; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors; Hypoxia-inducible factor-1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Ovarian cancer; Renal cell carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ovarian cancer; Renal cell carcinoma; Small cell lung cancer
  • Phase I/II Rectal cancer; Solid tumours
  • Preclinical Breast cancer
  • No development reported Gastric cancer; Non-small cell lung cancer

Most Recent Events

  • 07 Oct 2016 Pharmacokinetics data from a phase I trial in Solid tumour presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 07 Oct 2016 Interim efficacy and adverse event data from a phase I trial in Solid tumour presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 07 Oct 2016 Efficacy and adverse events data from a phase I/II trial in Ovarian cancer presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top